In a meta-analysis of three trials that compared an anti-PD1/PD-L1 immunotherapy to a second- or third-line chemotherapy with docetaxel, 185 patients had EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.